Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.46 |
| ▸ | NSD2 | O96028 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103881 | 0.99 | AR (0.47) | ARNSD2CYP19A1SLC22A12 | |
| SCHEMBL4107781 | 0.86 | AR (0.49) | ARNSD2CYP19A1 | |
| SCHEMBL4092323 | 0.85 | AR (0.48) | ARCYP19A1 | |
| SCHEMBL4093007 | 0.85 | AR (0.50) | ARCYP19A1 | |
| SCHEMBL4103627 | 0.85 | AR (0.52) | ARHRH3 | |
| SCHEMBL4098033 | 0.84 | AR (0.49) | ARCYP19A1 | |
| SCHEMBL4098544 | 0.84 | AR (0.51) | ARNSD2CYP19A1HRH1HRH3 | |
| SCHEMBL4099600 | 0.83 | AR (0.53) | AR | |
| SCHEMBL4102693 | 0.83 | AR (0.56) | ARNSD2 | |
| SCHEMBL4097672 | 0.83 | AR (0.47) | ARCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | SMITHKLINE BEECHMA CORPORATION (US) | 2009-04-09 | — | — | US | claimed |
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | SMITHKLINE BEECHMA CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | SMITHKLINE BEECHMA CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | SMITHKLINE BEECHMA CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1851204-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SmithKline Beecham Corporation (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006091592-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | NR3C1, NR3C2, NR5A1 | AR 38/4885NSD2 3017/4885CYP19A1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.